Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Drug discovery benefits from evaporative crystallization technology
January 2016
SHARING OPTIONS:

Genevac
 
A technical poster produced by Genevac, in conjunction with the Novartis Institute for BioMedical Research, examines the application of eXalt evaporative crystallization technology to drug discovery projects.
 
eXalt is a proprietary Genevac technology designed to control evaporation using restricting baffles. Using this technology, multiple solvents can be screened in parallel to identify optimum crystallization conditions for amorphous materials.
 
The scope of the research described in the poster was to investigate the suitability of Genevac eXalt evaporative crystallization technology for production of seed crystals from amorphous materials and to use these large crystals for structure determination, identification of solvates/solvation exchange, identify polymorphs and to undertake co-crystal screening.
 
The researchers conclude that eXalt technology was shown to be a versatile tool and successfully applied to novel compound classes in multiple drug discovery projects. Further, as a non-destructive technique enabling structure confirmation data to be obtained from samples as small as 5mg, eXalt is well suited for use in the optimization phase of early research projects.
 
Genevac

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.